Discovery of novel targets and therapeutics for Crohn’s disease
7 January 2016 | By Nicholas Jackson
Enterome announces collaboration with Johnson & Johnson Innovation focused on the discovery of novel targets and therapeutics for Crohn’s disease...
List view / Grid view
News
Complix and MSD team up for cell-penetrating alphabodies
6 January 2016 | By Victoria White
Complix will use its proprietary Alphabody platform to deliver cell-penetrating alphabodies against up to two intracellular cancer targets of interest to MSD...
Dasatinib shows promise in Duchenne muscular dystrophy
6 January 2016 | By Victoria White
Researchers tested the drug, commonly used to treat leukaemia, in zebrafish bred to carry Duchenne muscular dystrophy and recorded a 40% improvement in the condition of the fish...
Project launched for CAR-T cell immuno-oncology therapy development
6 January 2016 | By Victoria White
The Cell Therapy Catapult, the University of Birmingham and Cancer Research Technology have launched the project to develop a new immuno-oncology cellular therapy based on gene modifying T-cells to target solid tumours...
Takeda and Enterome enter microbiome drug discovery collaboration
6 January 2016 | By Victoria White
As part of the collaboration, Enterome will use its metagenomic platform to support the discovery of potential novel agents derived from gut bacteria and directed to gastrointestinal targets...
Oncodesign and BMS enter drug discovery collaboration
5 January 2016 | By Victoria White
Oncodesign and Bristol-Myers Squibb have entered into a strategic collaboration to discover, develop and commercialise novel macrocyclic compounds...
Renova expands its robust gene therapy intellectual property portfolio
5 January 2016 | By Victoria White
Renova and Research Development Foundation (RDF) have entered into a worldwide exclusive license agreement for RDF's portfolio of urocortin and stresscopin genes, as well as select peptides and proteins...
Nanobiotix to explore NBTXR3 in immuno-oncology
5 January 2016 | By Victoria White
NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumours, in combination with radiotherapy...
AIC649 shows potential to induce functional cure in preclinical HBV study
5 January 2016 | By Victoria White
AIC649 is an inactivated parapoxvirus ovis particle preparation with distinct immunological activities including regulated cytokine release and activation of T-cell responses...
CanSAR cancer drug discovery database goes 3D
4 January 2016 | By Victoria White
The updated canSAR database will allow scientists working in the UK and across the globe to design new cancer treatments more effectively...
Cellectis files clinical trial application for UCART19 in leukaemia
4 January 2016 | By Victoria White
UCART19 is a potential best-in-class allogeneic Talen gene edited T-cell product for treatment of CD19 expressing haematological malignancies...
Baxalta and Symphogen enter immuno-oncology collaboration
4 January 2016 | By Victoria White
As part of the collaboration agreement, Symphogen is to receive $175 million upfront, in addition to potential future milestone payments and royalties...
Memory drug BPN14770 moves into Phase 1 safety trial
4 January 2016 | By Victoria White
BPN14770 may be a possible treatment for dementia and Alzheimer’s disease with less potential for side effects than rolipram...
Vertex and Genomics enter target pathway collaboration
4 January 2016 | By Victoria White
Vertex Pharmaceuticals is to use Genomic’s integrated database and state-of-the-art analysis tools to identify target therapeutic pathways...
Drug generates exciting results in metastatic breast cancer models
23 December 2015 | By Victoria White
A team at CSHL has announced preclinical data suggesting the promise of a novel drug directed against a novel target in malignant mammary tumours...
